المؤلفون: F. Peyvandi, A. Cannavò, I. Garagiola, R. Palla, P.M. Mannucci, F.R. Rosendaal, A. El‐Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M. Elisa Mancuso, A.C. Sandoval Gonzalez, J.N. Mahlangu, S. Bonanad Boix, M. Cerqueira, N.P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N.L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakl, M.J. Manco‐Johnson, M. Martinez, E. Marzouka, M.G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B.M. Wicklund, B. Zulfikar

المصدر: Journal of Thrombosis and Haemostasis, 16(1), 39-43

مصطلحات موضوعية: Male, medicine.medical_specialty, Time Factors, Haemophilia A, 030204 cardiovascular system & hematology, Haemophilia, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, hemic and lymphatic diseases, Internal medicine, medicine, Humans, antibodies, plasma, Randomized Controlled Trials as Topic, Hematology, biology, Coagulants, business.industry, Incidence (epidemiology), Hazard ratio, medicine.disease, Antibodies, Neutralizing, Recombinant Proteins, Surgery, inhibitor, Treatment Outcome, factor VIII, Child, Preschool, Recombinant DNA, biology.protein, hemophilia A, Antibody, business, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640e6d6d7df07c14f529a85aa52dfa2b
https://doi.org/10.1111/jth.13888

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.